Skip to main content
HCPCS J9060 · Level II · Part B drug

HCPCS J9060: Injection, cisplatin, powder or solution, 10 mg

Reviewed by QuickIntell RCM Editorial Team · Last reviewed

Data effective
Data currency: ASP payment limits October 2026 (effective October 1, 2026); MUE and NCCI edits 2026 Q4 (effective October 1, 2026); OPPS Addendum B July 2026 (effective July 1, 2026). Next CMS release: January 1, 2027 (ASP, MUE, NCCI and OPPS quarterly updates).

Key facts for J9060

Billing unit
10 MG
Cisplatin 10 mg injection
ASP payment limit
$2.497
October 2026; +17.2% vs July 2026
Practitioner MUE
24
MAI 3
OPPS status
SI N
NCCI exposure
no PTP pairs
Coverage articles
0
none list this code

TL;DR

HCPCS J9060 is the Level II code for Injection, cisplatin, powder or solution, 10 mg, billed per 10 MG. The Medicare Part B ASP payment limit for October 2026 is $2.497 per billing unit, up 17.2% from July 2026. The practitioner MUE allows up to 24 units per date of service (MAI 3). Under OPPS it carries status indicator N. The 10 mg billing unit means doses are reported in multiples of ten milligrams, with any remainder rounded per contractor policy; mismatched units against the NDC quantity trigger MUE and NDC-unit edits. The ASP crosswalk maps 19 NDCs to it, sold as Cisplatin by Hikma Pharmaceuticals USA Inc., Teva Parenteral Medicines, Inc., Accord Healthcare Inc. No current Billing and Coding Article lists J9060, so coverage follows the FDA label, compendia and any applicable NCD.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for J9060 at $2.497 per 10 MG for October 2026, derived from manufacturer average sales price plus 6%, compared with $2.13 in July 2026. Beneficiary coinsurance is 20%.

ASP payment limits for J9060
QuarterPayment limitPerCoinsurance
October 2026$2.49710 MG20%
July 2026$2.1310 MG—
Source: CMS Medicare Part B Drug Payment Limit File. Commercial and Medicaid payers set their own rates.

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 19 NDCs from 9 labelers to J9060. Report the NDC in the claim's drug segment and bill the number of J9060 units that equals the quantity administered divided by 10 MG; the last column gives units per full package.

NDCs that crosswalk to J9060
NDCDrug nameLabelerPackage sizeBilling units / package
00143-9504-01CisplatinHikma Pharmaceuticals USA Inc.50 × 15
00143-9505-01CisplatinHikma Pharmaceuticals USA Inc.100 × 110
00703-5747-11CisplatinTeva Parenteral Medicines, Inc.50 × 15
00703-5748-11CisplatinTeva Parenteral Medicines, Inc.100 × 110
16729-0288-11CisplatinAccord Healthcare Inc50 × 15
16729-0288-38CisplatinAccord Healthcare Inc100 × 110
25021-0253-50CisplatinSagent Pharmaceuticals50 × 15
25021-0253-51CisplatinSagent Pharmaceuticals100 × 110
44567-0511-01CisplatinWG Critical Care, LLC200 × 120
44567-0530-01CisplatinWG Critical Care, LLC1 × 15
60505-6279-00CisplatinApotex Corp50 × 15
63323-0103-51CisplatinFreseniUS Kabi USA, LLC50 × 15
63323-0103-64CisplatinFreseniUS Kabi USA, LLC200 × 120
63323-0103-65CisplatinFreseniUS Kabi USA, LLC100 × 110
68001-0283-32CisplatinBluePoint Laboratories100 × 110
68001-0608-24CisplatinBluePoint Laboratories50 × 15
68001-0609-33CisplatinBluePoint Laboratories100 × 110
72266-0252-01CisplatinFosun Pharma USA Inc.50 × 15
72266-0253-01CisplatinFosun Pharma USA Inc.100 × 110

Medically Unlikely Edits (MUE)

CMS publishes 3 MUE values for J9060. For practitioners the limit is 24 units per date of service with adjudication indicator 3, a date-of-service clinical edit: units above the limit deny but can be paid on appeal with documentation that the quantity was medically reasonable.

MUE values for J9060 by setting
SettingMUE (units/DOS)MAICMS rationale
Practitioner services243 Date of Service Edit: ClinicalPrescribing Information
Facility outpatient hospital243 Date of Service Edit: ClinicalPrescribing Information
DME supplier03 Date of Service Edit: ClinicalCMS Policy

NCCI edits and add-on relationships

No active practitioner PTP pair lists J9060 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

J9060 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

No current Billing and Coding Article lists J9060 in its HCPCS table. Coverage then follows the drug's FDA label, compendia and any National Coverage Determination; check the Medicare Coverage Database before administering off-label.

Hospital outpatient (OPPS) status

In the July 2026 OPPS Addendum B, J9060 carries status indicator N. Status N means payment is packaged into the associated procedure and no separate OPPS payment is made.

Common denials for J9060 and how to prevent them

CARC 16 · M119

NDC missing, invalid or not matched to the HCPCS code

CARC 151 · N362

units billed exceed the MUE for the date of service

CARC 50 · N115

diagnosis not covered by the applicable coverage article or LCD

How QuickIntell checks J9060 before the claim leaves

QuickCode validates the NDC-to-unit conversion against the current ASP crosswalk, checks units against every published MUE setting and flags PTP and add-on conflicts on the same claim. QuickRCM routes CARC 16, 151 and 50 denials on drug lines with the matching coverage article attached so the appeal starts with evidence.

Explore QuickCodeExplore QuickRCMBook a demo

Frequently asked questions — HCPCS J9060

What does HCPCS code J9060 describe?

J9060 is defined by CMS as "Injection, cisplatin, powder or solution, 10 mg". Each billing unit represents 10 MG, so the units reported on the claim must equal the dose administered divided by that unit.

What is the Medicare reimbursement for J9060 in October 2026?

The ASP-based payment limit is $2.497 per 10 MG, with 20% beneficiary coinsurance. Medicare Administrative Contractors apply this limit; commercial payers use their own fee schedules. The July 2026 limit was $2.13.

How many units of J9060 can be billed per day?

The practitioner Medically Unlikely Edit is 24 units per date of service with adjudication indicator 3 (3 Date of Service Edit: Clinical). MAI 3 edits can be appealed with documentation that the units were medically reasonable. CMS cites "Prescribing Information" as the rationale.

Which NDCs map to J9060?

The October 2026 ASP crosswalk lists 19 NDCs from 9 labelers: Cisplatin (Hikma Pharmaceuticals USA Inc.); Cisplatin (Teva Parenteral Medicines, Inc.); Cisplatin (Accord Healthcare Inc); Cisplatin (Sagent Pharmaceuticals). For example NDC 00143-9504-01 is a 50 package equal to 5 billing units. The crosswalk's billing-units-per-package figure converts each package into J9060 units.

Does J9060 have NCCI bundling edits?

No active practitioner PTP pairs list J9060 as a column-1 or column-2 code in the v323r0 release. Unit limits (MUE) and medical-necessity coverage rules still apply.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-10-01. Verify against the primary file before billing or contracting decisions.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B and the Medicare Coverage Database. Payment limits are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.